SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
KING OF PRUSSIA, Pa., March 29, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m. EDT in New York.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
